SCHEMBL578574

SCHEMBL578574

C=CC[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL620472 1.00
SCHEMBL29854799 1.00
SCHEMBL315363 1.00
Ammonia Solution, Strong SCHEMBL169584 0.97
Methylamine SCHEMBL8997149 0.94
Ammonia Solution, Strong SCHEMBL28958150 0.91
Urea SCHEMBL10685728 0.87 GRIK1 (0.38)
SCHEMBL3678694 0.81 TSHR (0.33)
SCHEMBL3678696 0.81 TSHR (0.33)
Alcohol SCHEMBL9844307 0.79 ALDH1A1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703802-B2 Process for the preparation of aryl substituted olefinic amines TARGACEPT, INC. (US) 2014-04-22 US claimed
EP-4747249-A1 TREM2 MODULATORS Muna Therapeutics ApS (DK) 2026-05-27 EP disclosed
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 US disclosed
WO-2025202022-A9 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-12-26 WO disclosed
WO-2025202022-A1 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-10-02 WO disclosed
US-12428425-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2025-09-30 US disclosed
WO-2025132542-A1 MACROCYCLIC OREXIN AGONISTS IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-26 WO disclosed
WO-2025128873-A1 HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
US-20250188089-A1 SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-06-12 US disclosed
US-20250179091-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-06-05 US disclosed
EP-1056458-A1 METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN Wake Forest University (US) 2000-12-06 EP disclosed
WO-2000062767-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT, INC. (US) 2000-10-26 WO disclosed
EP-1042274-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-10-11 EP disclosed
WO-2000023418-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-04-27 WO disclosed
WO-2000007600-A1 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R.J. REYNOLDS TOBACCO COMPANY (US) 2000-02-17 WO disclosed
WO-1999065876-A1 ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS R.J. REYNOLDS TOBACCO COMPANY (US) 1999-12-23 WO disclosed
WO-1999043322-A1 METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN WAKE FOREST UNIVERSITY (US) 1999-09-02 WO disclosed
US-5223633-A Deprotonating a carbamate; chelation with diamine; removal of protecting group BAYER AKTIENGESELLSCHAFT (DE) 1993-06-29 US disclosed
US-4225507-A 19-Hydroxy-19-methyl-PGI2 compounds THE UPJOHN COMPANY (US) 1980-09-30 US disclosed
US-4225508-A 19-Hydroxy-PGI2 compounds THE UPJOHN COMPANY (US) 1980-09-30 US disclosed